Cargando…

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

BACKGROUND: Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herbrich, Shelley, Baran, Natalia, Cai, Tianyu, Weng, Connie, Aitken, Marisa J L, Post, Sean M, Henderson, Jared, Shi, Chunhua, Havranek, Ondrej, Richard-Carpentier, Guillame, Sauvageau, Guy, Baggerly, Keith, Al-Atrash, Gheath, Davis, R Eric, Daver, Naval, Zha, Dongxing, Konopleva, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323398/ https://www.ncbi.nlm.nih.gov/pubmed/34326171 http://dx.doi.org/10.1136/jitc-2021-002968

Ejemplares similares

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
por: Short, Nicholas J., et al.
Publicado: (2023)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
por: Short, Nicholas J., et al.
Publicado: (2022)

EMBR-33. YAP1 FUNCTION IN SHH MEDULLOBLASTOMA PROGRESSION AND IMMUNE EVASION
por: Abdelfattah, Nourhan, et al.
Publicado: (2021)

Targeting FLT3 mutations in AML: review of current knowledge and evidence
por: Daver, Naval, et al.
Publicado: (2019)

TSH-TSHR axis promotes tumor immune evasion
por: Wu, Zhenghao, et al.
Publicado: (2022)

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
por: Kannan, Sankaranarayan, et al.
Publicado: (2022)

Correction: Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
Publicado: (2021)

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
por: Collins, Natalie B, et al.
Publicado: (2022)

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022)

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
por: Zhang, Biying, et al.
Publicado: (2023)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
por: Travelli, Cristina, et al.
Publicado: (2023)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021)

Targeting stromal cell Syndecan‐2 reduces breast tumour growth, metastasis and limits immune evasion
por: Loftus, Paul G., et al.
Publicado: (2020)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
por: Yu, Jiongjie, et al.
Publicado: (2023)

Poster: AML-108: Exogenous Mitochondrial Transfer and Endogenous Mitochondrial Fission Facilitate Resistance to OxPhos Inhibition in AML
por: Tabe, Yoko, et al.
Publicado: (2021)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
por: Alotaibi, Ahmad S., et al.
Publicado: (2020)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES
por: Popat, Uday R., et al.
Publicado: (2023)

Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones: A retrospective study of 93 patients
por: van der Heijden, L, et al.
Publicado: (2012)

Custom osteotomy guides for resection of a pelvic chondrosarcoma
por: Blakeney, William G, et al.
Publicado: (2014)

Giant Cell Tumor (GCT) of Capitate
por: Narayana Gowda, BS, et al.
Publicado: (2012)

Metastatic adenocarcinoma of Proximal Femur treated by Custom made Hip Prosthesis
por: Pal, Chandra Prakash, et al.
Publicado: (2012)

Surgery of non-spinal skeletal metastases in renal cell carcinoma
por: Ratasvuori, Maire, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d8sfpatdaa00eh2krs8mkpjttp